Molecular imaging suggests efficacy of bevacizumab beyond the second line in advanced colorectal cancer patients

G. Brandi, M. Nannini, M. A. Pantaleo, S. Fanello, M. Farsad, S. Fanti, G. Ercolani, A. Maleddu, M. Di Battista, G. Biasco

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We report the clinical history of a female affected by advanced colorectal cancer (CRC). The patient was treated with five subsequent therapeutic schedules (FOLFIRI, FOLFOXIRI, FOLFIRI, FOLFOX4, FOLFOX4 plus cetuximab) because of the progression of the disease. The sixth treatment was bevacizumab in combination with 5-fluorouracil and irinotecan (FOLFIRI). The CT scan and the FDG-PET/CT performed 3 months after the beginning of the treatment showed that some, even if not all, lesions had a reduction of both size and metabolic activity. After the second revaluation the disease progressed. This short report suggests that the response of CRC to antiangiogenetic therapy may also occur after several unsuccessful antineoplastic treatments. Different biological features may explain the nonhomogeneous objective response of the metastatic lesions. Molecular imaging techniques seem to be mandatory in the era of tailored therapy since it is useful to have an in vivo 'biological picture' of the neoplastic disease.

Original languageEnglish
Pages (from-to)421-424
Number of pages4
JournalChemotherapy
Volume54
Issue number6
DOIs
Publication statusPublished - Oct 2008

Fingerprint

Molecular Imaging
Colorectal Neoplasms
irinotecan
Therapeutics
Fluorouracil
Antineoplastic Agents
Disease Progression
Bevacizumab
Appointments and Schedules
History

Keywords

  • Advanced colorectal cancer
  • Bevacizumab
  • PET

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery

Cite this

Brandi, G., Nannini, M., Pantaleo, M. A., Fanello, S., Farsad, M., Fanti, S., ... Biasco, G. (2008). Molecular imaging suggests efficacy of bevacizumab beyond the second line in advanced colorectal cancer patients. Chemotherapy, 54(6), 421-424. https://doi.org/10.1159/000158540

Molecular imaging suggests efficacy of bevacizumab beyond the second line in advanced colorectal cancer patients. / Brandi, G.; Nannini, M.; Pantaleo, M. A.; Fanello, S.; Farsad, M.; Fanti, S.; Ercolani, G.; Maleddu, A.; Di Battista, M.; Biasco, G.

In: Chemotherapy, Vol. 54, No. 6, 10.2008, p. 421-424.

Research output: Contribution to journalArticle

Brandi, G, Nannini, M, Pantaleo, MA, Fanello, S, Farsad, M, Fanti, S, Ercolani, G, Maleddu, A, Di Battista, M & Biasco, G 2008, 'Molecular imaging suggests efficacy of bevacizumab beyond the second line in advanced colorectal cancer patients', Chemotherapy, vol. 54, no. 6, pp. 421-424. https://doi.org/10.1159/000158540
Brandi, G. ; Nannini, M. ; Pantaleo, M. A. ; Fanello, S. ; Farsad, M. ; Fanti, S. ; Ercolani, G. ; Maleddu, A. ; Di Battista, M. ; Biasco, G. / Molecular imaging suggests efficacy of bevacizumab beyond the second line in advanced colorectal cancer patients. In: Chemotherapy. 2008 ; Vol. 54, No. 6. pp. 421-424.
@article{45958e97390f47a7b30cb1559d43623b,
title = "Molecular imaging suggests efficacy of bevacizumab beyond the second line in advanced colorectal cancer patients",
abstract = "We report the clinical history of a female affected by advanced colorectal cancer (CRC). The patient was treated with five subsequent therapeutic schedules (FOLFIRI, FOLFOXIRI, FOLFIRI, FOLFOX4, FOLFOX4 plus cetuximab) because of the progression of the disease. The sixth treatment was bevacizumab in combination with 5-fluorouracil and irinotecan (FOLFIRI). The CT scan and the FDG-PET/CT performed 3 months after the beginning of the treatment showed that some, even if not all, lesions had a reduction of both size and metabolic activity. After the second revaluation the disease progressed. This short report suggests that the response of CRC to antiangiogenetic therapy may also occur after several unsuccessful antineoplastic treatments. Different biological features may explain the nonhomogeneous objective response of the metastatic lesions. Molecular imaging techniques seem to be mandatory in the era of tailored therapy since it is useful to have an in vivo 'biological picture' of the neoplastic disease.",
keywords = "Advanced colorectal cancer, Bevacizumab, PET",
author = "G. Brandi and M. Nannini and Pantaleo, {M. A.} and S. Fanello and M. Farsad and S. Fanti and G. Ercolani and A. Maleddu and {Di Battista}, M. and G. Biasco",
year = "2008",
month = "10",
doi = "10.1159/000158540",
language = "English",
volume = "54",
pages = "421--424",
journal = "Chemotherapy",
issn = "0009-3157",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Molecular imaging suggests efficacy of bevacizumab beyond the second line in advanced colorectal cancer patients

AU - Brandi, G.

AU - Nannini, M.

AU - Pantaleo, M. A.

AU - Fanello, S.

AU - Farsad, M.

AU - Fanti, S.

AU - Ercolani, G.

AU - Maleddu, A.

AU - Di Battista, M.

AU - Biasco, G.

PY - 2008/10

Y1 - 2008/10

N2 - We report the clinical history of a female affected by advanced colorectal cancer (CRC). The patient was treated with five subsequent therapeutic schedules (FOLFIRI, FOLFOXIRI, FOLFIRI, FOLFOX4, FOLFOX4 plus cetuximab) because of the progression of the disease. The sixth treatment was bevacizumab in combination with 5-fluorouracil and irinotecan (FOLFIRI). The CT scan and the FDG-PET/CT performed 3 months after the beginning of the treatment showed that some, even if not all, lesions had a reduction of both size and metabolic activity. After the second revaluation the disease progressed. This short report suggests that the response of CRC to antiangiogenetic therapy may also occur after several unsuccessful antineoplastic treatments. Different biological features may explain the nonhomogeneous objective response of the metastatic lesions. Molecular imaging techniques seem to be mandatory in the era of tailored therapy since it is useful to have an in vivo 'biological picture' of the neoplastic disease.

AB - We report the clinical history of a female affected by advanced colorectal cancer (CRC). The patient was treated with five subsequent therapeutic schedules (FOLFIRI, FOLFOXIRI, FOLFIRI, FOLFOX4, FOLFOX4 plus cetuximab) because of the progression of the disease. The sixth treatment was bevacizumab in combination with 5-fluorouracil and irinotecan (FOLFIRI). The CT scan and the FDG-PET/CT performed 3 months after the beginning of the treatment showed that some, even if not all, lesions had a reduction of both size and metabolic activity. After the second revaluation the disease progressed. This short report suggests that the response of CRC to antiangiogenetic therapy may also occur after several unsuccessful antineoplastic treatments. Different biological features may explain the nonhomogeneous objective response of the metastatic lesions. Molecular imaging techniques seem to be mandatory in the era of tailored therapy since it is useful to have an in vivo 'biological picture' of the neoplastic disease.

KW - Advanced colorectal cancer

KW - Bevacizumab

KW - PET

UR - http://www.scopus.com/inward/record.url?scp=52549092180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52549092180&partnerID=8YFLogxK

U2 - 10.1159/000158540

DO - 10.1159/000158540

M3 - Article

C2 - 18824847

AN - SCOPUS:52549092180

VL - 54

SP - 421

EP - 424

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3157

IS - 6

ER -